The American Journal of Managed Care

Quantitative CT Predicts Progression, Nintedanib Effect in PPF

Quantitative computed tomography (CT) methods can help predict disease progression and assess the efficacy of drugs in ...

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

Trial did not meet the primary endpoint of annualized rate of FVC decline –– Axatilimab was well tolerated with a safety profile comparable to ...

Syndax Pharmaceuticals suffers pipeline blow

Syndax Pharmaceuticals Inc. SNDX announced it will halt the clinical development of axatilimab in idiopathic pulmonary ...
Healio

Nerandomilast lowers FVC decline in progressive pulmonary fibrosis at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...
Healio

Nerandomilast reduces FVC decline, has ‘manageable’ adverse events in IPF at 52 weeks

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing nerandomilast doses were assessed against ...
The American Journal of Managed Care

The Impact of FVC Decline and Lung Function in IPF

Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...

Can FVC decline and worsening prognosis be predicted in advance? ILD risk assessment opened up by quantitative CT analysis (STP, QILD, QGG)

In this study, we evaluated the utility of Single Time Point (STP) prediction scores and computed tomography (CT)-based ...